Newborn Screening for Mucopolysaccharidosis I: Moving Forward Learning from Experience

Area of Science:

• Biomedical Science
• Genetics
• Public Health

Background:

• Mucopolysaccharidosis I (MPS I) is a rare genetic disorder.
• Newborn screening (NBS) programs are increasingly incorporating MPS I detection.
• Initial single-tier screening approaches for MPS I have shown limitations.

Purpose of the Study:

• To evaluate the effectiveness of a second-tier biomarker in MPS I newborn screening.
• To highlight the need for improved precision in MPS I newborn screening.
• To advocate for the adoption of enhanced screening protocols for MPS I and other mucopolysaccharidoses.

Main Methods:

• Integration of a second-tier biomarker into the existing MPS I newborn screening protocol.
• Evaluation of the impact of the second-tier biomarker on screening precision and predictive value.
• Comparative analysis of single-tier versus second-tier screening approaches.

Main Results:

• The second-tier biomarker significantly improved the precision of MPS I newborn screening.
• Enhanced predictive value was observed with the integrated second-tier biomarker approach.
• The study identified shortcomings in single-tier screening that necessitate remediation.

Conclusions:

• A second-tier biomarker is crucial for accurate and reliable newborn screening for MPS I.
• Newborn screening programs should adopt multi-tier strategies for MPS I and other lysosomal storage disorders.
• Implementation of second-tier biomarkers will enhance the overall effectiveness of newborn screening initiatives.